|
Sep 24
|
IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans
|
|
Sep 23
|
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma
|
|
Sep 22
|
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024
|
|
Aug 26
|
IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
|
|
Aug 1
|
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Jul 31
|
IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen
|
|
Jul 31
|
Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program
|
|
Jul 29
|
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event
|
|
Jul 23
|
How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%
|
|
Jun 25
|
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer
|
|
Jun 24
|
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
|
|
Jun 18
|
Investors in IDEAYA Biosciences (NASDAQ:IDYA) have seen impressive returns of 277% over the past five years
|
|
May 8
|
IDEAYA Biosciences First Quarter 2024 Earnings: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)
|
|
May 7
|
IDEAYA Biosciences Inc (IDYA) Reports Q1 2024 Earnings: Financial and Strategic Developments
|
|
May 7
|
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 1
|
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
|
|
Apr 24
|
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
|
|
Apr 22
|
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
|
|
Apr 1
|
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
|
|
Mar 27
|
TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
|